Recom Board Member Presents at Ceremony Honoring Artificial Organ Pioneers; Recognized as Dean of Prestigious ``International Academy of Artificial Organ Pioneers''.

Business Editors/Health/Medical Writers

LOS ANGELES--(BUSINESS WIRE)--July 1, 2003

Dr. Lowell T. Harmison, a member of the Board of Directors of Recom Managed Systems, Inc. (OTCBB:RECM), presented at the prestigious ceremony honoring Artificial Organ Pioneers on June 18, 2003.

Dr. Harmison was recognized as the Dean of the Prestigious "International Academy of Artificial Organ Pioneers" whose membership and sponsorship includes the top and most renowned cardiac-surgeons in the world.

At the presentation, Dr. Harmison outlined the importance of technologies such as those possessed by Recom, as he highlighted the crucial nature of true ambulatory monitoring in our current society. As mentioned in Recom's prior press releases, Dr. Harmison developed and patented the first fully implantable artificial heart. At the Ceremony, Dr. Harmison commented:

"We are on the leading edge of many technological breakthroughs that will advance the opportunities and contributions that artificial organs can make in sustaining quality of life and reducing the burden of disease. They range from the ability to get enhanced cardiac diagnostic information in an ambulatory setting, to ATM type machines for getting personal and general health care information and to more implantable smaller artificial hearts.

"The use of 12 or more lead electrocardiography including wireless signal transmission will truly advance the field. It will allow for effective diagnostic cardiac monitoring on a 24/7 basis for use outside of the office, hospital and clinic environment. Coronary artery disease is one of the most common manifestations in adult heart disease. The ability to have in an ambulatory setting a rapid, accurate and cost-effective evaluation of what is occurring in a 12 or more lead diagnostic monitor, represents an important change for the future diagnosis of the state of heart disease. This capacity will add to the cornerstone strengths of more catheter-based approaches for assisting in separating patients who present with all of the symptoms, i.e. chest pains that are suggestive of acute or coronary artery disease. This technology may allow for the reduction of the number presenting with similar symptoms, but who do not have coronary disease. This will give an important earlier opportunity to intervene in their disease and hopefully save their lives and add additional years of quality to their lives. The field needs diagnostic information with high predictive value of the disease. One should remember that coronary artery disease influences more than 10 million Americans every year, with over 5 million emergency room visits."

These comments and outlooks continue to cause the Company to believe that it is currently on the cutting edge -- and beyond the state of the art -- in its field and it is anxiously anticipating the move forward toward regulatory and marketing approval for its models and devices. As Dr. Harmison noted after the Ceremony: "Heart transplant is the last and end state step in a process that may be avoided if earlier detected and successfully treated, i.e., coronary artery disease. The problem is early and accurate detection. With the strides Recom has made -- well ahead of schedule and my personal expectations -- I am confident that the beginning of the era of preventative heart diagnosis through better monitoring is all but upon us."

About the International Academy of Artificial Organ Pioneers

The International Academy of Artificial Organ Pioneers (IAAOP) was created to assist in the advancement of the artificial organs field by working to reduce barriers, enhance educational opportunities and give perspectives on issues that affect the role of artificial organs in the fields of medicine and health. Specifically, the purpose is:

-- To recognize and honor pioneering contributors to the

field of artificial organs;

-- To advance research, development and educational issues

concerning artificial organs;

-- To promote greater understanding of artificial organs by

patients, caregivers and society; and

-- To support artificial organ history interests and to

assist in documentation of achievements and museum

activities.

The IAAOP is organized as a legal entity through the International Center for Medical Technologies (ICMT) of the State of Texas. The IAAOP organizational structure consists of a Dean (Lowell T. Harmison), a Medical Affairs Dean (Denton A. Cooley), an Engineering Affairs Dean (William Murphy), and Associate Deans representing ASAIO, ISAO, EuSAO, JSAO, ISRBP, ISA and elected pioneer members of IAAOP. IAAOP's founding members were elected on the basis of their seminal contributions and service to the field of artificial organs and activity participation in the program and dedication of the ICMT Museum at the Herman Memorial Hospital in Houston, Texas, on November 8, 2002. It functions through an Executive Committee under the chairmanship of the International Academy's Dean. All officers are elected for a two-year period.

The International Academy recognizes pioneers who have made seminal contributions to advance the field. These are the individuals on whose shoulders we stand to see new horizons, to make new advancements and to find ways of applying artificial organs to reduce the burden of disease, accidents and assaults on healthy living. The list of founding pioneers is extensive and covers contributions made around the world by internationally renowned surgeons and health care professionals.

About Recom Managed Systems, Inc.

Recom Managed Systems, Inc., a Delaware corporation, is an emerging life sciences company. In September 2002, Recom completed a technology acquisition for purposes of attempting to develop and then commercialize heart monitoring devices. Notwithstanding this transaction, Recom intends for the foreseeable future to remain a development-stage company with negligible cash or other tangible assets, no currently outstanding debt and no immediate prospects of revenue. Recom will require substantial additional money to fund further development and continue with attempts to commercialize the technology into products and services. Recom cannot provide assurances that any of these endeavors will be successful.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Recom's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approvals governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Recom's products or services, adverse equity market conditions and declines in the value of Recom's common stock, and the unavailability of financing to complete management's plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Recom's filings with the Securities and Exchange Commission.